Literature DB >> 9049884

p53 protein in pediatric malignant astrocytomas: a study of 21 patients.

M B Bhattacharjee1, J M Bruner.   

Abstract

Malignant astrocytomas are uncommon brain tumors in children and it is known that astrocytic tumors with similar degrees of histologic anaplasia often show different biologic behaviour. Their uncommon occurrence has resulted in relatively few studies of the molecular biology and genetics of pediatric malignant astrocytomas with somewhat conflicting results, in contrast with the many studies addressing astrocytomas in adults. p53 immunoreactivity has been used to screen tissues for the abnormal presence of the p53 protein and abnormal immunoreactivity has been demonstrated in one-half to two-thirds of adult astrocytomas. We studied the frequency of p53 immunoreactivity and gene alteration in 21 children with malignant astrocytomas (anaplastic astrocytoma and glioblastoma multiforme) and analysed the survival of patients with p53 immunoreactive versus non-reactive tumors. Of the cases examined, 8 were anaplastic astrocytoma (AA) and 13 were glioblastoma multiforme (GM). We found that the overall frequency of p53 immunoreactivity of 47% in this group of pediatric malignant astrocytomas is similar to that reported for adult astrocytomas. The median survival in both p53-positive and p53-negative groups of pediatric malignant astrocytomas was similar: however, the number of deaths in each group and the distribution of p53 scores is not statistically significant. Further studies to precisely identify p53 and other genetic mutations in pediatric gliomas are needed to understand their biology and the rationale for therapeutic options.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049884     DOI: 10.1023/a:1005727902387

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  41 in total

Review 1.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

2.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

3.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

4.  Germline p53 gene mutations in subsets of glioma patients.

Authors:  A P Kyritsis; M L Bondy; M Xiao; E L Berman; J E Cunningham; P S Lee; V A Levin; H Saya
Journal:  J Natl Cancer Inst       Date:  1994-03-02       Impact factor: 13.506

5.  Gain of function mutations in p53.

Authors:  D Dittmer; S Pati; G Zambetti; S Chu; A K Teresky; M Moore; C Finlay; A J Levine
Journal:  Nat Genet       Date:  1993-05       Impact factor: 38.330

6.  Supratentorial pilocytic astrocytomas. A clinicopathologic, prognostic, and flow cytometric study of 51 patients.

Authors:  P A Forsyth; E G Shaw; B W Scheithauer; J R O'Fallon; D D Layton; J A Katzmann
Journal:  Cancer       Date:  1993-08-15       Impact factor: 6.860

7.  Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme.

Authors:  A von Deimling; D N Louis; K von Ammon; I Petersen; T Hoell; R Y Chung; R L Martuza; D A Schoenfeld; M G Yaşargil; O D Wiestler
Journal:  J Neurosurg       Date:  1992-08       Impact factor: 5.115

8.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

Authors:  K V Chin; K Ueda; I Pastan; M M Gottesman
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

9.  Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms.

Authors:  T J Montine; J M Bruner; J J Vandersteenhoven; R K Dodge; P C Burger
Journal:  Diagn Mol Pathol       Date:  1994-12

10.  p53 protein in low-grade astrocytomas: a study with long-term follow-up.

Authors:  P Iuzzolino; C Ghimenton; A Nicolato; F Giorgiutti; P Fina; C Doglioni; M Barbareschi
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more
  6 in total

1.  H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance.

Authors:  Alok Mohan Uppar; Harsha Sugur; A R Prabhuraj; M Bhaskara Rao; B Indira Devi; S Sampath; A Arivazhagan; Vani Santosh
Journal:  Childs Nerv Syst       Date:  2019-05-31       Impact factor: 1.475

2.  Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study.

Authors:  G Fountzilas; A Karavelis; A Capizzello; A Kalogera-Fountzila; G Karkavelas; N Zamboglou; P Selviaridis; G Foroglou; A Tourkantonis
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases.

Authors:  C H Rickert; R Sträter; P Kaatsch; H Wassmann; H Jürgens; B Dockhorn-Dworniczak; W Paulus
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

4.  MGMT gene promoter methylation in pediatric glioblastomas.

Authors:  Arti Srivastava; Ayushi Jain; Prerana Jha; Vaishali Suri; Mehar Chand Sharma; Supriya Mallick; Tarun Puri; Deepak Kumar Gupta; Aditya Gupta; Chitra Sarkar
Journal:  Childs Nerv Syst       Date:  2010-06-29       Impact factor: 1.475

5.  Absence of germline and somatic p53 alterations in children with sporadic brain tumors.

Authors:  C Portwine; S Chilton-MacNeill; C Brown; E Sexsmith; J McLaughlin; D Malkin
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

6.  A study of histopathological spectrum and expression of Ki-67, TP53 in primary brain tumors of pediatric age group.

Authors:  Subhalakshmi Sengupta; Uttara Chatterjee; Uma Banerjee; Samarendranath Ghosh; Sandip Chatterjee; Ashit K Ghosh
Journal:  Indian J Med Paediatr Oncol       Date:  2012-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.